You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 (abstract O17). Treatment-related AEs with BMS-986178 and BMS-986178 + nivolumab

From: 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One

  1. aGrade 3 treatment-related pneumonitis was reported in 1 patient treated with BMS-986178 160 mg + nivolumab 240 mg.